Sarfaraz K. Niazi, PhD, congratulates the FDA on approving the 50th biosimilar, noting that there's more work to be done to expand the market.
End of April 2024, the FDA made a significant announcement that it had approved 50 biosimilars 14 years after the Biologics Price Competition and Innovation Act (BPCIA) went into effect. While this is a hallmark moment, it remains an incomplete promise and hope related to biosimilars.
The FDA has approved biosimilars for only 15 molecules out of over 100 biologics that have had patents expired—and dozens more to join this list of candidates. The US-approved biosimilars are held mainly by big pharma companies as they can easily afford the cost of hundreds of millions of dollars for their approval.
However, the high development cost also means that biosimilars will remain high as these investments are amortized. The FDA can change the fate of biosimilars dramatically by adopting scientific rationality despite the misconstrued requirements listed in the BPCIA for biosimilar approval; the legislation gives the FDA that authority. Alas, some elements cannot be altered, such as the designation of interchangeable biosimilars, a classification that the US maintains with a few least-developed countries. There are legislative attempts to remove this despite the strong opposition by big pharma. So, until then, I believe the FDA should give interchangeable status to all first-time filers of a molecule—this will bring a deluge of new biosimilars.
Further, this approval should come without clinical efficacy testing that is now well-proven and redundant based on simple statistical calculations—no wonder these studies never fail because they cannot. The analytical assessment and clinical pharmacology profiling are more than enough to demonstrate the safety and efficacy of biosimilars. What is holding back is not any argument over the scientific merits of these suggestions but the conservative close-mindedness of the reviewers that is continuously instigated by the big pharma.
I wish to congratulate the FDA for reaching this milestone; I would be happier if the FDA had used this event to announce changes in the development requirements and become the leader in scientific pursuit.
New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers
June 11th 2024Posters from the American Society of Clinical Oncology annual meeting showcased safety and efficacy data for a trastuzumab biosimilar and an ado-trastuzumab biosimilar in HER2-positive (HER2+) cancers.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilars Council Position Paper Calls for End to Clinical Efficacy Trials for Biosimilars
June 4th 2024In a position paper from the Biosimilars Council, the organization points to evidence showing that clinical efficacy trials are a major barrier to biosimilar access in the US, calling for the FDA to change its policies to remove them in favor of other comparators.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use
May 21st 2024Posters from Digestive Disease Week (DDW) on the ongoing LIBERTY-CD trial assessing Zymfentra, a subcutaneous infliximab product, compared with intravenous infliximab treatment in Crohn disease show the safety and efficacy of the product, as well as the impact of body mass index (BMI) on clinical outcomes.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.